|
|
Volumn 375, Issue 2, 2016, Pages 187-188
|
|
The authors reply
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
SURFACTANT;
OXYGEN;
CLINICAL EFFECTIVENESS;
CONTROLLED CLINICAL TRIAL (TOPIC);
DISABILITY;
GESTATIONAL AGE;
HIGH RISK PATIENT;
HUMAN;
INFANT;
LETTER;
META ANALYSIS (TOPIC);
MORTALITY;
OXIMETER;
OXYGEN SATURATION;
OXYGENATION;
PHASE 2 CLINICAL TRIAL (TOPIC);
POSITIVE END EXPIRATORY PRESSURE;
POST HOC ANALYSIS;
PREDICTIVE VALUE;
PRIORITY JOURNAL;
RISK FACTOR;
SAFETY;
THERAPY EFFECT;
BLOOD;
FEMALE;
MALE;
OXYGEN THERAPY;
PREMATURITY;
PROCEDURES;
RETINOPATHY OF PREMATURITY;
FEMALE;
HUMANS;
INFANT, EXTREMELY PREMATURE;
INFANT, PREMATURE, DISEASES;
MALE;
OXYGEN;
OXYGEN INHALATION THERAPY;
RETINOPATHY OF PREMATURITY;
|
|
EID: 84978372605
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMc1604023 Document Type: Letter |
|
Times cited : (3)
|
|
References (5)
|
